Institutional
Foresite Capital Management IV, LLC
CIK 0001704132
$237.1M
Reported AUM
8
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Foresite Capital Management IV, LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management IV, LLC established a new position in Eikon Therapeutics, Inc. EIKN valued at $20.56M. The fund also increased its stake in CYTOKINETICS INC CYTK by 9.82%. Conversely, the fund trimmed its holding in Maze Therapeutics, Inc. MAZE by 69.98%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Ticker | Issuer | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | $135.0M | 56.94% | — | HELD |
| 2 | CYTK | CYTOKINETICS INC | $33.2M | 13.99% | +45,000 | +9.8% |
| 3 | EIKN | Eikon Therapeutics, Inc. | $20.6M | 8.67% | +1,943,682 | NEW |
| 4 | LYEL | Lyell Immunopharma, Inc. | $16.1M | 6.77% | — | HELD |
| 5 | RLAY | Relay Therapeutics, Inc. | $9.9M | 4.20% | — | HELD |
| 6 | XENE | Xenon Pharmaceuticals Inc. | $9.3M | 3.92% | — | HELD |
| 7 | ALEC | Alector, Inc. | $8.4M | 3.53% | — | HELD |
| 8 | MAZE | Maze Therapeutics, Inc. | $4.7M | 1.98% | -365,756 | -70.0% |
Source: SEC EDGAR · accession 0001104659-26-062462. 13F discloses long positions only — shorts, foreign equities, and options are excluded.